HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Carter-Wallace

This article was originally published in The Rose Sheet

Executive Summary

Carter-Wallace: President and Chief Operating Officer Daniel Black will retire March 31, 1997. A successor has not yet been announced by the company's board of directors. Net sales for the company's FY 1997 first quarter (ended June 30) decreased 4% to $169.9 mil. The company noted that unit sales were "lower overall" in the consumer products segment, which includes the Arrid and Lady's Choice antiperspirant brands as well as Nair depilatories and Pearl Drops tooth whiteners. Carter-Wallace net earnings for the quarter were $9.3 mil. versus $861,000 a year-ago because of a one-time charge related to the closure of the company's condom plant in the prior-year period. Excluding the one-time charge, FY 1997 first quarter net earnings declined 27.2% from $12.7 mil. in the year-ago period...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel